MYC (8q24) Gene Rearrangement by FISH
Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (NHL) characterized by the translocation and deregulation of the MYC gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic (African), sporadic (non-endemic), and immunodeficiency associated. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features between the three forms.
Chronic Epstein-Barr virus (EBV) infection appears to play a role in virtually all cases of endemic (African) BL and a minority of sporadic and immunodeficiency-associated BL.
The development of BL is dependent upon the constitutive expression of the MYC proto-oncogene located at chromosome 8q24, which encodes the MYC protein transcription factor. In virtually all studies, BL is associated with a translocation between the long arm of chromosome 8 (8q24) and one of three locations on immunoglobulin (Ig) genes:
- The Ig heavy chain gene on chromosome 14 (about 80%) – t(8;14)
- The kappa light chain gene on chromosome 2 (about 15%) – t(2;8)
- The lambda light chain gene on chromosome 22 (about 5%) – t(8;22)
The diagnosis of BL is based upon the pathologic evaluation, immunophenotyping and cytogenetic analysis of involved tissue. MYC rearrangements can usually be detected by conventional cytogenetics, but can also be demonstrated by fluorescent in situ hybridization (FISH) using fluorescent probes that are commercially available. In the 2016 WHO classification of lymphoid neoplasms, diagnosis of BL in the absence of MYC rearrangement is disfavored. Tumors that show some atypical morphologic features but that have the immunophenotypic and genotypic features of BL should be categorized as BL.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL in the world, and accounts for 30%–40% of all adult NHLs. DLBCL is a heterogeneous, common type of aggressive B-cell lymphoma. MYC rearrangements can be detected in 9% of DLBCLs. In contrast to BL, MYC aberration usually occurs with complex karyotypes and with other cooperating genetic lesions such as BCL-2 and BCL-6 rearrangements, defining the so-called “double-hit” and “triple-hit” DLBCL. The MYC aberration is associated with a more aggressive phenotype and poor outcome, including shorter progression-free and overall survival. MYC aberrations represent the most reproducible biomarker with unfavorable prognosis. Screening MYC has definite prognostic meaning for DLBCL stratification, thus enabling more tailored therapy.
Most tumors that have rearrangements of MYC and BCL-2 and/or BCL-6 (so-called double or triple hit lymphomas) have been placed in a new category, "high grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements." Until optimal therapies are identified, authors recommend that clinicians obtain biopsy specimens from all newly diagnosed patients with DLBCL and that these be tested via fluorescence in situ hybridization to determine double-hit lymphoma (DHL) status.
- Diagnosis and management of Burkitt lymphoma
- Management of double-hit or triple-hit High Grade B-Cell Lymphoma (therapy selection and disease management)
- Rule out Burkitt lymphoma from other similar symptomatic lymphomas and leukemias
- As an aid in diagnosis of large B-cell lymphoma
- As an aid in the differentiation of Burkitt lymphoma from other aggressive B-cell lymphomas
- As an aid in the differentiation of cutaneous angiosarcomas from atypical vascular lesions after radiotherapy
I. In the Pediatric cases with classical morphology and immunophenotype (CD20(+), CD10(+), BCL-6(+), BCL-2(-), Ki-67>95%): To confirm the BL diagnosis, do MYC FISH assay:
- Positivity indicates BL once more. Do not forget MYC translocation is sensitive but not specific for BL. Under these circumstances, total diagnostic sensitivity is about 98%
- Negativity excludes BL. Under these circumstances, total diagnostic specificity is about 99%
II. In the cases with atypical morphology and immunophenotype (CD20(+), CD10(+), BCL6(+), Ki-67>90%):
- Do MYC FISH assay using Break Apart Probes to identify positive samples for MYC translocations (MYC translocation is sensitive but not specific for BL and upward of 10% of apparent BL do not have a typical translocation)
- If positive in the pediatric patient, diagnosis is BL * 80% is IGH-MYC * 15% is IGK-MYC * 5% is IGL-MYC * If negative in the pediatric patient, MYC/IGH probes should be tested simultaneously to increase detection rates by minimizing false negative results.
- If positive in the adult patient, then determine immunoglobulin partners of MYC through MYC-IGH, MYC-IGK and MYC-IGL Dual Color Dual Fusion Probes.
- If positive, then do BCL-2 and BCL-6 FISH assays through the use of Break Apart Probes
- Negativity of BCL-2 and BCL-6 means most probably BL * Positivity of BCL-2 and/or BCL-6 means most probably Intermediate BL/DLBCL
- If negative, then determine non-immunoglobulin partners of MYC (Non-IG-MYC) by FISH Positivity means most probably Intermediate BL/DLBCL regardless of BCL-2 and BCL-6 FISH positivity
- If negative in the adult patient, MYC/IGH probes should be tested simultaneously to increase detection rates by minimizing false negative results.
- Check BCL-2 staining and Ki-67 index and no need to do BCL-2 and BCL-6 FISH assays through Break Apart Probes
- If positive for BCL-2 staining and Ki-67<90%, diagnosis is most probably DLBCL
III. Based on clinical features, morphology, immunophenotype and Ki-67 index
- Negativity of MYC FISH and MYC/IGH FISH, lymphoma can be excluded.
- Negative MYC FISH: A normal nucleus with no 8q24 rearrangements. Break Apart Probes produces a two orange/green (yellow) fusion pattern
- Positive MYC FISH: An abnormal nucleus with 8q24 rearrangements (e.g. t(2;8), t(8;22) or t(8;14)). Break Apart Probes will produce one orange, one green, and one yellow fusion pattern. This probe does not identify partner chromosome, only rearrangement of the target sequence
- Peripheral blood: Draw in a sodium heparin tube and keep at room temperature until testing. 5-ml sample is adequate.
- Bone marrow aspirate: Draw in sodium heparinized syringe and transferred to a sodium heparin (green) tube. Keep at room temperature until testing. Between 1 and 3 ml of bone marrow is required. EDTA tubes are acceptable.
- Fine-Needle Aspiration (FNA) biopsy in RPMI 1640 media (2.0-4.0 mL)
- Fresh tissue in tissue culture medium (e.g. RPMI 1640)
- Specimens in RPMI 1640 medium should be held refrigerated and promptly shipped with a refrigerated gel pack. Specimens ideally should be received within 24-48 hours for best specimen stability and results.
- 10% neutral buffered formalin fixed paraffin embedded (FFPE) tissue
- Rejection criteria: Frozen, clotted, hemolyzed or contaminated specimens. Incorrect anticoagulant used. Frozen specimens or specimens fixed or processed in non-formalin fixatives or heavy metal fixatives. Fresh tissue specimens sent without tissue culture medium. Specimens arriving in the laboratory 4 days or more following the original collection date.
Stability
Maintain specimens at room temperature (20-25°C or 68-77°F) until transported to the lab. For delays in transport (greater than 24 from the time of collection), refrigerate (2-8°C or 36-46°F) the specimen.
- Ambient: 24 hours
- Refrigerated: 3-5 days
- J Pathol Inform. 2016;7:20. [PMID: 27217970]
- Cancer Treat Res. 2015;165:27-50. [PMID: 25655605]
- Infect Agent Cancer. 2013 Sep 30;8(1):37. [PMID: 24079473]
- Cancer. 2012 Mar 15;118(6):1566-73. [PMID: 21882178]
- Blood. 2015 Nov 26;126(22):2466-74. [PMID: 26373676]
- Ther Adv Hematol. 2016;7(1):52– 64 [PMID: 26834954]
- Cancer. 2016 Feb 15;122(4):559-64. [PMID: 26565895]
- Br J Haematol. 2016 Nov;175(4):631-640. [PMID: 27469075]
- Blood. 2016 May 19;127(20):2375-90. [PMID: 26980727]
- PLoS One. 2014 Apr 16;9(4):e95020. [PMID: 24740248]